UK Markets open in 2 hrs 40 mins

ReNeuron Group plc (RENE.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
36.00+0.50 (+1.41%)
At close: 04:29PM BST

ReNeuron Group plc

Pencoed Business Park
Pencoed CF35 5HY
United Kingdom
44 20 3819 8400

Full-time employees38

Key executives

NameTitlePayExercisedYear born
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.DExec. ChairmanN/AN/A1954
Dr. John David Sinden B.A., BA, M.A., MA, Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1951
Ms. Catherine Isted A.C.M.A.CFO & Exec. DirectorN/AN/AN/A
Ms. Suzanne HancockHead of OperationsN/AN/AN/A
Dr. Stefano PluchinoChief Scientific OfficerN/AN/AN/A
Mr. Shaun StapletonHead of Regulatory Affairs and VP of Regulatory Affairs & PharmacovigilanceN/AN/AN/A
John HawkinsCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Corporate governance

ReNeuron Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.